Follow us for updates
© 2022
Read the Story →

29,828 New Cases Logged as PH Gets Access to Cheaper COVID Pill

Here are the latest numbers.
by Erwin Colcol
3 days ago
Photo/s: Merck

The Philippines on Sunday logged 29,828 new COVID-19 cases as a cheaper version of Merck's anti-COVID pill will soon be supplied to the country.

The day's tally brought active cases to 273,580 with a total of 36,763 new recoveries and 67 new deaths reported.

Overall, a total of 3,417,216 COVID-19 cases have been reported since the pandemic began in March 2020, of which 3,090,164 have recovered and 53,472 died.

The global Medicines Patent Pool signed agreements with 27 manufacturers to produce the oral antiviral medicine molnupiravir which will be supplied to 105 low- and-middle-income countries, including the Philippines.

Merck granted a license to the MPP which, in turn, issued sub-licenses to the generic drug makers. The sub-licenses allow manufacturers to produce the raw ingredients for molnupiravir.

Molnupiravir is used for mild to moderate cases of COVID-19, and was shown to reduce hospitalization for newly infected patients by 50%.

The Philippine Food and Drug Administration in December gave Molnarz, a brand of molnupiravir, an emergency use authorization, allowing for its wider use. --- with reports from Agence France Presse

Continue reading below ↓


Merck's COVID Pill Hailed After Cutting Hospitalizations by Half

Ayala Health Plans to Sell World's First Anti-COVID Pill in the Philippines

Continue reading below ↓
Recommended Videos

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
'Sinungaling' and #LetLeniSpeak trended after the YouTube interview.
Households need to notify their local government.
One debate per month from February to April.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.